ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 109 citations in OpenAlex.
- Lipid Metabolic Rewiring During Continuous Prostate Cancer Progression Defines a Biologically Relevant Four-Gene Prognostic Signature.Biological procedures online · 2026Article
- Smooth Muscle Disruptive Feature Defines Molecular Subtyping, Risk Stratification, and Metastatic Potential in Prostate Cancer.Annals of surgical oncology · 2026Article
- Chromatin regulatorsChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Identification of functional genes and immune cell infiltration analysis in liposarcoma.PloS one · 2026Article
- Review
- Intratumoral Heterogeneity and Immune Microenvironment in Hepatoblastoma Revealed by Single-Cell RNA Sequencing.Journal of cellular and molecular medicine · 2025Article
- 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer.Frontiers in oncology · 2025Article
- The role of neuroendocrine differentiation in treatment resistance of prostate cancer and intervention strategies.Frontiers in oncology · 2025Review
- TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.Cancer biology & therapy · 2024Article
- Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.The Journal of clinical investigation · 2024Article
- Impact on natural history of atypical meningioma after changes in 2016 edition of the world health organization (WHO) classification of central nervous system tumors: a literature review.Neurosurgical review · 2024Review
- Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.Nature cell biology · 2024Article
- The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.Nature communications · 2024Article
- Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.Frontiers in oncology · 2024Review
- EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.Journal of experimental & clinical cancer research : CR · 2023Article
- Article
- Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.Journal of translational medicine · 2023Article
- BAZ2A-RNA mediated association with TOP2A and KDM1A represses genes implicated in prostate cancer.Life science alliance · 2023Article
- The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer research · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 1 institution in 1 country.
David P LabbéDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Christopher J SweeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Phillip GalboDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
Spencer RosarioDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
Kristine M WadoskyDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
Sheng-Yu KuDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
Martin SjöströmDepartment of Clinical Sciences, Oncology and Pathology, Lund University and Skåne University Hospital, Lund, Sweden.
Mohammed AlshalalfaGenomeDx Biosciences, Vancouver, British Columbia, Canada.
Nicholas ErhoGenomeDx Biosciences, Vancouver, British Columbia, Canada.
Elai DavicioniGenomeDx Biosciences, Vancouver, British Columbia, Canada.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Edward M SchaefferDepartment of Urology, Northwestern University, Illinois.
Robert B JenkinsDepartment of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ashley E RossTexas Urology Specialists, Dallas, Texas.
Michaela BowdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ying HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Kathryn P GrayDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Felix Y FengDepartment of Radiation Oncology, University of California at San Francisco, San Francisco, California.
Daniel E SprattDepartment of Radiation Oncology, Michigan Center for Translational Pathology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
David W GoodrichDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
Kevin H EngDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
Leigh EllisDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Massachusetts. leigh_ellis@dfci.harvard.edu.
Roswell Park Comprehensive Cancer Center · US
Funding
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MEnabling Access to Cutting-Edge Biomedical and Behavioral ScienceR25GM095459 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2012 to 2021
$4.4MExploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancerR01CA207757 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ELLIS, LEIGH, GOODRICH, DAVID W. · 2016 to 2020
$2.8M(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypesR21CA179907 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2013 to 2014
$401kNCI NIH HHS P30 CA016056NCI NIH HHS R01 CA207757NCI NIH HHS R21 CA179907NIGMS NIH HHS R25 GM095459
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorAnimalsCell Line, TumorComputational BiologyDisease ProgressionDNA Topoisomerases, Type IIEarly Detection of CancerEnhancer of Zeste Homolog 2 ProteinGene Expression ProfilingGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansKaplan-Meier EstimateMaleMiceMice, KnockoutBiomarkers, TumorDNA Topoisomerases, Type IIEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPoly-ADP-Ribose Binding ProteinsTOP2A protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.